Table 1 The results of reporting quality assessment (n = 487)
From: Quality of reporting of systematic reviews published in “evidence-based” Chinese journals
PRISMA items | Yes | Partial | No | ||||
|---|---|---|---|---|---|---|---|
n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI | ||
Title | 1. Title | 476 (98) | 96–99 | 1 (0) | 1–1 | 10 (2) | 1–4 |
Abstract | 2. Structured summary | 256 (53) | 48–57 | 226 (46) | 42–51 | 5 (1) | 0–2 |
Introduction | 3. Rational | 429 (88) | 85–91 | 55 (11) | 9–14 | 3 (1) | 0–2 |
4. Objective | 335 (69) | 65–73 | 143 (29) | 26–34 | 9 (2) | 1–4 | |
Methods | 5. Protocol and registration | 2 (0) | 0–2 | 58 (12) | 9–15 | 427 (88) | 85–90 |
6. Eligibility criteria | 447 (92) | 89–94 | 39 (8) | 6–11 | 1 (0) | 1–1 | |
7. Information sources | 480 (99) | 97–100 | 6 (1) | 0–23 | 1 (0) | 0–1 | |
8. Search | 263 (54) | 50–59 | 182 (37) | 33–41 | 42 (9) | 6–12 | |
9. Study selection | 241 (50) | 45–54 | 72 (15) | 12–18 | 174 (36) | 32–40 | |
10. Data collection process | 334 (69) | 64–73 | 45 (9) | 7–12 | 108 (22) | 19–26 | |
11. Data items | 203 (42) | 37–46 | 25 (5) | 4–8 | 259 (53) | 49–58 | |
12. Risk of bias in individual studies | 436 (90) | 87–92 | 17 (4) | 2–6 | 34 (7) | 5–10 | |
13. Summary measures | 444 (91) | 88–93 | 7 (1) | 0–3 | 36 (7) | 5–10 | |
14. Synthesis of results | 453 (93) | 90–95 | 7 (1) | 0–3 | 27 (6) | 4–8 | |
15. Risk of bias across studies | 161 (33) | 29–37 | 74 (15) | 12–19 | 252 (52) | 47–56 | |
16. Additional analyses | 253 (52) | 48–56 | 44 (9) | 7–12 | 190 (39) | 35–43 | |
Results | 17. Study selection | 356 (73) | 69–77 | 70 (14) | 12–18 | 61 (13) | 10–16 |
18. Study characteristics | 445 (91) | 89–94 | 21 (4) | 3–7 | 21 (4) | 3–7 | |
19. Risk of bias with studies | 423 (87) | 84–90 | 31 (6) | 5–9 | 33 (7) | 5–9 | |
20. Results of individual studies | 442 (91) | 88–93 | 24 (5) | 3–7 | 21 (4) | 3–7 | |
21. Synthesis of results | 442 (91) | 88–93 | 23 (5) | 3–7 | 22 (5) | 3–7 | |
22. Risk of bias across studies | 109 (22) | 19–26 | 94 (19) | 16–23 | 284 (58) | 54–63 | |
23. Additional analyses | 142 (29) | 25–33 | 56 (11) | 9–15 | 289 (59) | 55–64 | |
Discussion | 24. Summary of evidence | 440 (90) | 87–93 | 38 (8) | 6–11 | 9 (2) | 1–4 |
25. Limitations | 385 (79) | 75–83 | 42 (9) | 6–12 | 60 (12) | 10–16 | |
26. Conclusions | 394 (81) | 77–84 | 85 (18) | 14–21 | 8 (2) | 0–3 | |
Funding | 27. Funding | 119 (24) | 21–28 | 41 (8) | 6–11 | 327 (67) | 63–71 |
Total score | Scope | 8.5–26.0 | |||||
±SD | 19.60 ± 3.33 | ||||||